Switzerland-based respiratory biotech Windward Bio Group files for a $100 million US IPO
Windward Bio Group, a Switzerland-based Phase 2/3 biotech developing antibodies for respiratory and dermatologic diseases, filed on Friday with …​Read More
Windward Bio Group, a Switzerland-based Phase 2/3 biotech developing antibodies for respiratory and dermatologic diseases, filed on Friday with …​Read More
by Newsbot · Published October 23, 2026
by Newsbot · Published October 23, 2026
by Newsbot · Published October 23, 2026
by Newsbot · Published October 23, 2026
by Newsbot · Published October 22, 2026
by Newsbot · Published October 22, 2026
by Newsbot · Published October 22, 2026
by Newsbot · Published October 22, 2026
by Newsbot · Published October 22, 2026
by Newsbot · Published October 21, 2026
Follow:
